Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

H.C. Wainwright 5th Annual NASH Investor Conference, October 12, 2021
 Tuesday, October 12, 2021
 3:30pm - 4:30pm EDT